IRIS UniCatt

Baldin, Gianmaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.300
AS - Asia 968
EU - Europa 675
SA - Sud America 237
AF - Africa 30
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.246
SG - Singapore 416
CN - Cina 243
BR - Brasile 193
SE - Svezia 145
IT - Italia 142
FR - Francia 115
DE - Germania 89
VN - Vietnam 77
IN - India 54
BD - Bangladesh 52
FI - Finlandia 33
GB - Regno Unito 30
ID - Indonesia 30
IE - Irlanda 30
CA - Canada 29
JP - Giappone 27
AR - Argentina 21
PL - Polonia 17
HK - Hong Kong 15
MX - Messico 14
RU - Federazione Russa 14
KR - Corea 11
AT - Austria 10
TR - Turchia 10
ZA - Sudafrica 10
ES - Italia 9
CO - Colombia 7
EC - Ecuador 7
KE - Kenya 7
UA - Ucraina 7
BE - Belgio 6
LT - Lituania 5
IQ - Iraq 4
NL - Olanda 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CL - Cile 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
IR - Iran 2
JM - Giamaica 2
LV - Lettonia 2
MD - Moldavia 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
SA - Arabia Saudita 2
TW - Taiwan 2
UZ - Uzbekistan 2
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JO - Giordania 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
Totale 3.213
Salva come PNG Salva come JPEG
Città #
Singapore 232
Chandler 189
Ashburn 132
San Jose 128
New York 67
Beijing 40
Hefei 36
Rome 35
Dublin 30
Ho Chi Minh City 28
Los Angeles 28
Milan 28
The Dalles 28
Lauterbourg 27
St Louis 26
Tokyo 26
Redmond 25
San Mateo 25
Jakarta 23
Nanjing 22
Boston 21
São Paulo 21
Hanoi 19
Munich 18
Chicago 17
Frankfurt am Main 17
Cattolica 16
Helsinki 16
Dearborn 15
Princeton 15
Redwood City 15
Wilmington 14
Buffalo 13
Hong Kong 12
Jacksonville 12
Montreal 12
Marseille 11
Paris 11
Santa Clara 11
Brooklyn 10
Kent 10
Orem 10
Seoul 10
Turku 9
Atlanta 8
Guangzhou 8
Toronto 8
Warsaw 8
Bexley 7
Changsha 7
Mumbai 7
Vienna 7
Belo Horizonte 6
Boardman 6
Brussels 6
Chennai 6
Denver 6
London 6
Moscow 6
Shenyang 6
Tianjin 6
Da Nang 5
Johannesburg 5
Las Vegas 5
Mexico City 5
Washington 5
Buenos Aires 4
Düsseldorf 4
Houston 4
Jiaxing 4
Jinan 4
Kraków 4
Lappeenranta 4
Nairobi 4
Nanchang 4
Palermo 4
Phoenix 4
Poplar 4
Querétaro 4
Shanghai 4
Stockholm 4
Alcalá de Henares 3
Augusta 3
Biên Hòa 3
Brasília 3
Campinas 3
Fairfield 3
Guarulhos 3
Haiphong 3
Lawrence 3
Little Rock 3
Mountain View 3
New Delhi 3
Nuremberg 3
Ottawa 3
Portland 3
Quito 3
Ribeirão Preto 3
Rio de Janeiro 3
Roubaix 3
Totale 1.766
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 157
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 144
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 142
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 140
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 140
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 139
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 137
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 135
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 132
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 130
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 126
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 120
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 119
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 118
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 116
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 113
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 108
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 107
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 105
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice 99
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 98
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 96
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis 95
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV 92
Necrotizing mpox with persistent microbiological positivity despite the use of tecovirimat: A case report 89
Autochthonous dengue outbreak in Rome, Italy, in 2023 87
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 85
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 82
Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy 5
Real-World Application of Recommended Practices in Nocardiosis 5
Bridging the gap: addressing real-life challenges to the implementation of DTG/3TC in treatment-naive people living with HIV 4
Use of Tobacco and Alternative Nicotine Products Among People with HIV: A Cross-Sectional Multicenter Survey 4
Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study 3
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort 1
Totale 3.273
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.813
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022155 4 0 4 24 5 6 0 27 3 15 25 42
2022/2023438 63 65 38 61 24 46 25 40 54 1 11 10
2023/2024221 13 40 4 20 4 79 6 6 1 8 21 19
2024/2025562 13 8 46 28 46 28 45 19 46 41 137 105
2025/20261.492 191 52 93 216 252 65 225 58 83 108 45 104
2026/202743 43 0 0 0 0 0 0 0 0 0 0 0
Totale 3.273